Exonhit to Acquire Redpath Integrated Pathology, Inc.
Complementary fit between RedPath’s DNA platform and ExonHit’s RNA platform
27-Apr-2010 -
ExonHit Therapeutics S.A. announced that it entered into a binding agreement for the acquisition of RedPath Integrated Pathology, Inc., a privately held molecular diagnostics company, focused on cancer. RedPath will become part of ExonHit’s US operations.
Headquartered in Pittsburgh, ...
diagnostic tests
DNA mutation
gene mutations
+6